Immunotherapy in inoperable stage III non-small cell lung cancer: a review

by Natasha A Jain, Gregory A Otterson
Published 2019-06-01

Agents to treat BRAF-mutant lung cancer

by Jean G Bustamante Alvarez, Gregory A Otterson
Published 2019-03-01

Metastatic Squamous Cell Carcinoma Component from an Adenosquamous Carcinoma of the Lung with Identical Epidermal Growth Factor Receptor Mutations

by Jarred Burkart, Konstantin Shilo, Weiqiang Zhao, Efe Ozkan, Amna Ajam, Gregory A. Otterson
Published 2015-01-01

Fanconi Anemia repair pathway dysfunction, a potential therapeutic target in lung cancer

by Wenrui eDuan, Li eGao, Brittany eAguila, Arjun eKalvala, Gregory A Otterson, Miguel Angel Villalona
Published 2014-12-01

Altered p16INK4 and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer

by Weiqiang Zhao, Cheng C. Huang, Gregory A. Otterson, Marino E. Leon, Yan Tang, Konstantin Shilo, Miguel A. Villalona
Published 2012-01-01

Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer

by Howard Burris, Joe Stephenson, Gregory A. Otterson, Mark Stein, Jesse McGreivy, Yu-Nien Sun, Megan Ingram, Yining Ye, Lee S. Schwartzberg
Published 2011-01-01

A novel classification of lung cancer into molecular subtypes.

by Lisandra West, Smruti J Vidwans, Nicholas P Campbell, Jeff Shrager, George R Simon, Raphael Bueno, Phillip A Dennis, Gregory A Otterson, Ravi Salgia
Published 2012-01-01

Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer.

by Romulo M Brena, Carl Morrison, Sandya Liyanarachchi, David Jarjoura, Ramana V Davuluri, Gregory A Otterson, David Reisman, Selina Glaros, Laura J Rush, Christoph Plass
Published 2007-03-01

Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice.

by Wenrui Duan, Li Gao, Xin Wu, Erinn M Hade, Jian-Xin Gao, Haiming Ding, Sanford H Barsky, Gregory A Otterson, Miguel A Villalona-Calero
Published 2009-01-01

Clinical and Metabolic Parameters in Non-Small Cell Lung Carcinoma and Colorectal Cancer Patients with and without KRAS Mutations

by Ahmet Yilmaz, Nehad Mohamed, Kara A. Patterson, Yan Tang, Konstantin Shilo, Miguel A. Villalona-Calero, Michael E. Davis, Xiao-Ping Zhou, Wendy Frankel, Gregory A. Otterson, Weiqiang Zhao
Published 2014-08-01

A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC

by Justin F. Gainor, MD, Shirish Gadgeel, M.B.B.S., Sai-Hong I. Ou, MD, PhD, Beow Yeap, ScD, Gregory A. Otterson, MD, Alice T. Shaw, MD, PhD
Published 2020-09-01

Increased NQO1 but Not c-MET and Survivin Expression in Non-Small Cell Lung Carcinoma with KRAS Mutations

by Ahmet Yilmaz, Nehad Mohamed, Kara A. Patterson, Yan Tang, Konstantin Shilo, Miguel A. Villalona-Calero, Michael E. Davis, Xiaoping Zhou, Wendy Frankel, Gregory A. Otterson, Howard D. Beall, Weiqiang Zhao
Published 2014-09-01

Global Methylation Profiling of Lung Cancer Identifies Novel Methylated Genes

by Zunyan Dai, Romola R. Lakshmanan, Wei-Guo Zhu, Dominic J. Smiraglia, Laura J. Rush, Michael C. Frühwald, Romulo M. Brena, Bin Li, Fred A. Wright, Patrick Ross, Gregory A. Otterson, Christoph Plass
Published 2001-01-01

Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database

by Eric D Miller, James L Fisher, Karl E Haglund, John C Grecula, Meng Xu-Welliver, Erin M Bertino, Kai He, Peter G Shields, David P Carbone, Terence M Williams, Gregory A Otterson, Jose G Bazan
Published 2018-10-01

HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells.

by Guolin Chai, Lian Li, Wen Zhou, Lipeng Wu, Ying Zhao, Donglai Wang, Shaoli Lu, Yu Yu, Haiying Wang, Michael A McNutt, Ye-Guang Hu, Yingqi Chen, Yang Yang, Xin Wu, Gregory A Otterson, Wei-Guo Zhu
Published 2008-06-01

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

by Daniel Spakowicz, Rebecca Hoyd, Mitchell Muniak, Marium Husain, James S. Bassett, Lei Wang, Gabriel Tinoco, Sandip H. Patel, Jarred Burkart, Abdul Miah, Mingjia Li, Andrew Johns, Madison Grogan, David P. Carbone, Claire F. Verschraegen, Kari L. Kendra, Gregory A. Otterson, Lang Li, Carolyn J. Presley, Dwight H. Owen
Published 2020-05-01

Correction: Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

by Jacob J. Chabon, Andrew D. Simmons, Alexander F. Lovejoy, Mohammad S. Esfahani, Aaron M. Newman, Henry J. Haringsma, David M. Kurtz, Henning Stehr, Florian Scherer, Chris A. Karlovich, Thomas C. Harding, Kathleen A. Durkin, Gregory A. Otterson, W. Thomas Purcell, D. Ross Camidge, Jonathan W. Goldman, Lecia V. Sequist, Zofia Piotrowska, Heather A. Wakelee, Joel W. Neal, Ash A. Alizadeh, Maximilian Diehn
Published 2016-11-01

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

by Jacob J. Chabon, Andrew D. Simmons, Alexander F. Lovejoy, Mohammad S. Esfahani, Aaron M. Newman, Henry J. Haringsma, David M. Kurtz, Henning Stehr, Florian Scherer, Chris A. Karlovich, Thomas C. Harding, Kathleen A. Durkin, Gregory A. Otterson, W. Thomas Purcell, D. Ross Camidge, Jonathan W. Goldman, Lecia V. Sequist, Zofia Piotrowska, Heather A. Wakelee, Joel W. Neal, Ash A. Alizadeh, Maximilian Diehn
Published 2016-06-01